OncoPharm

Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia. The mechanism of this ADR as well as the implications of which anti-diabetes medications are used in response is discussed.

Review article: https://doi.org/10.1177/15347354211073163

Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's podcast discusses a recent meta-analysis on the benefit of a "neutropenic diet" in patients on treatment for cancer. Link: https://doi.org/10.1200/OP-26-00405

The 2026 World Conference on Lung Cancer just wrapped up. We run through the findings of the most notable trials presented at WCLC.

Download the Learning Oncology Companion:https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Press Releases are an increasingly common method to learn about new/upcoming data. What can clinicians learn (and what can't we learn) from these? We read through two examples for just this purpose.

Example 1: https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer

Example 2: https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-reports-93-clinical-benefit-rate-mipletamig-triplet

Possible Help with Drug Shortages: https://www.angelsforchange.org

Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML.

Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too.

Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's pod has everything:
1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer
2. A new standard of care (?) in HER(+) gastric cancers, and more nuance on HER2 positivity. And lots of diarrhea.
3. The largest RCT in primary CNS lymphoma

Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm